Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany.
This study evaluated factors that influence the cost-effectiveness of talazoparib, particularly for patients with a germline breast-cancer-gene-(brca)-mutation and locally advanced or metastasized breast cancer within the context of the German healthcare system. We constructed a partitioned survival...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0278460 |
| _version_ | 1797856340519944192 |
|---|---|
| author | Florian Schwarz Habibollah Arefian Michael Hartmann Ingo Runnebaum |
| author_facet | Florian Schwarz Habibollah Arefian Michael Hartmann Ingo Runnebaum |
| author_sort | Florian Schwarz |
| collection | DOAJ |
| description | This study evaluated factors that influence the cost-effectiveness of talazoparib, particularly for patients with a germline breast-cancer-gene-(brca)-mutation and locally advanced or metastasized breast cancer within the context of the German healthcare system. We constructed a partitioned survival model to compare medical costs and treatment effectiveness for patients with such cancers over 45 months. Transition probabilities were derived from survival data from a randomized Phase-III EMBRACA trial, utilities based on published reports, and costs in Euros, which included costs for drug acquisition, clinical monitoring, and treatment of adverse events. Willingness-to-pay thresholds were set to be multiples of the current German per capita gross domestic product. Treatment with talazoparib led to a gain of 0.32 life-years (0.22 quality-adjusted life-years). The mean total cost of €84,003 for talazoparib and €12,741 for standard therapy resulted in an incremental cost-effectiveness ratio of €223,246 per life-year and €323,932 per quality-adjusted life-year gained, indicating that talazoparib is unlikely to be cost-effective at current pricing. |
| first_indexed | 2024-04-09T20:38:53Z |
| format | Article |
| id | doaj.art-3e60e117ecb84f9fba9ca632f2ec9eab |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-09T20:38:53Z |
| publishDate | 2022-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-3e60e117ecb84f9fba9ca632f2ec9eab2023-03-30T05:31:31ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-011712e027846010.1371/journal.pone.0278460Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany.Florian SchwarzHabibollah ArefianMichael HartmannIngo RunnebaumThis study evaluated factors that influence the cost-effectiveness of talazoparib, particularly for patients with a germline breast-cancer-gene-(brca)-mutation and locally advanced or metastasized breast cancer within the context of the German healthcare system. We constructed a partitioned survival model to compare medical costs and treatment effectiveness for patients with such cancers over 45 months. Transition probabilities were derived from survival data from a randomized Phase-III EMBRACA trial, utilities based on published reports, and costs in Euros, which included costs for drug acquisition, clinical monitoring, and treatment of adverse events. Willingness-to-pay thresholds were set to be multiples of the current German per capita gross domestic product. Treatment with talazoparib led to a gain of 0.32 life-years (0.22 quality-adjusted life-years). The mean total cost of €84,003 for talazoparib and €12,741 for standard therapy resulted in an incremental cost-effectiveness ratio of €223,246 per life-year and €323,932 per quality-adjusted life-year gained, indicating that talazoparib is unlikely to be cost-effective at current pricing.https://doi.org/10.1371/journal.pone.0278460 |
| spellingShingle | Florian Schwarz Habibollah Arefian Michael Hartmann Ingo Runnebaum Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany. PLoS ONE |
| title | Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany. |
| title_full | Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany. |
| title_fullStr | Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany. |
| title_full_unstemmed | Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany. |
| title_short | Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany. |
| title_sort | cost effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in germany |
| url | https://doi.org/10.1371/journal.pone.0278460 |
| work_keys_str_mv | AT florianschwarz costeffectivenessoftalazoparibforpatientswithlocallyadvancedormetastasizedbreastcanceringermany AT habibollaharefian costeffectivenessoftalazoparibforpatientswithlocallyadvancedormetastasizedbreastcanceringermany AT michaelhartmann costeffectivenessoftalazoparibforpatientswithlocallyadvancedormetastasizedbreastcanceringermany AT ingorunnebaum costeffectivenessoftalazoparibforpatientswithlocallyadvancedormetastasizedbreastcanceringermany |